Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tata Memorial Hospital
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Rigshospitalet, Denmark
Centre Antoine Lacassagne
Centre Antoine Lacassagne
University of Colorado, Denver
Memorial Sloan Kettering Cancer Center
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Michigan
Thomas Jefferson University
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
King Saud University
Sunnybrook Health Sciences Centre
University of Chicago
Cairo University
Oslo University Hospital
Klus Pharma Inc.
Fox Chase Cancer Center
Rigshospitalet, Denmark
Quadriga Biosciences, Inc.
Rutgers, The State University of New Jersey
Tata Memorial Hospital
Region Örebro County
Memorial Sloan Kettering Cancer Center
Vigilant Biosciences, Inc.
University of California, San Francisco
Rutgers, The State University of New Jersey
Indiana University
American College of Radiology Imaging Network
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Radiation Therapy Oncology Group
Hospital de Clinicas de Porto Alegre
Stanford University
Fuda Cancer Hospital, Guangzhou
Mayo Clinic
Abramson Cancer Center at Penn Medicine
Alliance for Clinical Trials in Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins